Epirubicin and Thalidomide in Treating Patients With Liver Cancer
Completed · Phase 2
Conditions studied: Liver Cancer
In brief
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with thalidomide in treating patients who have unresectable or metastatic liver cancer.
Key facts
- Study ID
- NCT00058487
- Run by
- Dana-Farber Cancer Institute
- People needed
- 12
- Starts
- 2001-12-01
- Expected to finish
- 2007-01-01
- Last updated by the study team
- 2013-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.